10-Q: Stryker Reports Q1 2026 Results, Net Sales Up 2.6%

Stryker Corporation announced its first quarter 2026 financial results, with net sales increasing by 2.6% to $6.02 billion, driven by higher unit volumes across key segments.

Summary

• Stryker Corporation reported net sales of $6.02 billion for the first quarter of 2026, a 2.6% increase compared to $5.87 billion in the same period of 2025.
• Net earnings for the quarter were $745 million, or $1.93 per diluted share, up from $654 million, or $1.69 per diluted share, in the prior year.
• The company experienced a cybersecurity incident on March 11, 2026, which caused disruptions and had a material impact on operations and financial results for the quarter.
• Despite the cybersecurity incident, global manufacturing operations have resumed, and commercial, ordering, and distribution systems have been restored.
• MedSurg and Neurotechnology segment sales grew 5.0% to $3.21 billion, while Orthopaedics segment sales saw a slight increase of 0.1% to $2.81 billion.
• Gross profit margin decreased to 63.3% from 63.8% in the prior year, primarily due to higher manufacturing and supply chain costs related to the cybersecurity incident.
• The company completed the acquisition of Amplitude Vascular Systems, Inc. (AVS) for approximately $435 million in cash plus up to $400 million in future milestone payments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with solid top-line growth and increased net earnings, partially offset by margin compression due to a significant cybersecurity incident.

Positives

• Net sales increased by 2.6% to $6.02 billion, exceeding the prior year's $5.87 billion.
• Net earnings rose to $745 million ($1.93 per diluted share) from $654 million ($1.69 per diluted share) in the prior year.
• MedSurg and Neurotechnology segment sales showed strong growth of 5.0%.
• Orthopaedics segment sales, despite a slight overall increase, benefited from a 4.1% constant currency increase driven by unit volume.
• The company successfully restored commercial, ordering, and distribution systems following a cybersecurity incident.
• Stryker completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), expanding its presence in the vascular business.

Negatives

• Gross profit margin declined to 63.3% from 63.8% due to increased manufacturing and supply chain costs linked to the cybersecurity incident.
• The cybersecurity incident on March 11, 2026, caused business disruptions and had a material impact on financial results.
• Operating income margin for MedSurg and Neurotechnology decreased to 21.8% from 24.8%.
• Operating income margin for Orthopaedics decreased slightly to 30.1% from 30.4%.
• Interest expense increased by 8.0% due to debt issuances in 2025.

Risks

• The ongoing investigation into the March 11, 2026 cybersecurity incident may lead to further adverse impacts, including financial, reputational, or otherwise.
• Future cybersecurity breaches, unauthorized access, or disruptions could materially affect business, financial condition, and results of operations.
• The company's reliance on IT systems and third-party vendors exposes it to risks of failure, breach, and disruption.
• Interruption of manufacturing operations due to various factors, including cybersecurity incidents, could adversely affect product availability and market share.
• Macroeconomic and geopolitical environments, including tariffs, slower economic growth, market volatility, and inflation, pose risks to business operations.
• The company is involved in various ongoing legal proceedings, the outcomes of which could result in significant claims, settlements, or injunctions.

Future Outlook

The company's goal is to achieve sales growth at the high-end of the medical technology industry and maintain its long-term capital allocation strategy prioritizing acquisitions, dividends, and share repurchases. Forward-looking statements are subject to risks and uncertainties, including the impact of the cybersecurity incident.

Management Comments

• "In the first quarter 2026 we achieved sales growth of 2.6% from 2025. Excluding the impact of acquisitions and divestitures, sales grew 1.0% in constant currency."
• "We reported operating income margin of 15.5%, net earnings of $745 and net earnings per diluted share of $1.93."
• "Excluding the impact of certain items, adjusted operating income margin contracted by 180 basis points to 21.1%, with adjusted net earnings of $1,004 and adjusted net earnings per diluted share of $2.60, a decrease of 8.5% from 2025."
• "By bringing Mako, power tools, cutting accessories, enabling technologies and the teams behind these products together under one business, we are simplifying the customer experience and striving to increase our speed to market through focused innovation."

Industry Context

StockSavvy.ai notes that Stryker's performance in Q1 2026, with a 2.6% overall sales growth, aligns with the generally stable but competitive nature of the medical technology industry. The company's strategic reorganization into 'Ortho Tech' reflects a trend towards specialization and customer-centricity within the orthopaedics sector.

Comparison to Industry Standards

• Stryker's reported net sales growth of 2.6% for Q1 2026 is a moderate increase within the medical technology sector, which typically sees growth rates ranging from low single digits to mid-teens depending on product cycles and market dynamics.
• The company's operating income margin of 15.5% is generally competitive within the broader healthcare equipment and supplies industry, though specific benchmarks vary significantly by sub-sector (e.g., implants vs. surgical instruments).
• The impact of the cybersecurity incident on gross profit margin (a 50 basis point decrease) highlights a common operational risk faced by many companies in the tech-enabled healthcare space, where supply chain and manufacturing disruptions can have a tangible effect on profitability.

Legal Proceedings

• The company is involved in various ongoing proceedings, legal actions, and claims arising in the normal course of business, including matters related to product, labor, tax, and intellectual property.

Stakeholder Impact

• Shareholders: Increased net earnings and EPS are positive for shareholders. The cybersecurity incident poses a risk to future performance and stock price.
• Employees: The cybersecurity incident may have caused operational disruptions. Management changes related to organizational structure could impact roles.
• Customers: While systems have been restored, the cybersecurity incident may have caused temporary disruptions in ordering or delivery.
• Suppliers: Potential disruptions from the cybersecurity incident could impact supply chain operations.

Next Steps

• Continue to monitor and evaluate the impact of the cybersecurity incident.
• Integrate Amplitude Vascular Systems, Inc. (AVS) into the Vascular business.
• Continue to monitor and evaluate the impact of macroeconomic and geopolitical environments, including tariffs and trade policies.
• Continue to evaluate the impact of new accounting pronouncements.

Key Dates

Recommendation

The company demonstrates solid revenue growth and improved net earnings, but the material impact of the cybersecurity incident on margins and operations, along with ongoing legal and regulatory risks, warrants a cautious approach. The acquisition of AVS is a positive strategic move, but its full impact is yet to be seen. A 'hold' recommendation reflects the balance between positive financial performance and the significant operational and security risks.

Keywords

Stryker, 10-Q, Quarterly Report, Medical Technology, MedSurg, Neurotechnology, Orthopaedics, Net Sales, Net Earnings, Cybersecurity Incident, Acquisition, Amplitude Vascular Systems